The therapeutic potential of ADAM10 and ADAM17 has already been exploited [3,79,80], and targeting these ADAMs genetically by antibodies or pharmacological inhibitors has been shown to suppress cell proliferation and tumor growth in various pre-clinical cancer models ([81]; for review, see [39,41,79,82]). This evidence concerns the gene ADAM10 and cancer.